



**BioLight Life Sciences Ltd.
(The "Company")**

28 March 2022

**To:
Israel Security Authority**

www.isa.goc.il

**TASE- Tel Aviv Stock Exchange
www.tase.co.il**

**Re: Signing of an exclusive distribution agreement for the marketing of the
Lipicare's Ocular D product in Israel (Subsidiary)**

The Company is hereby proud to announce that on March 27, 2022, Lipicare Pharmaceuticals Ltd., a subsidiary of the Company ("BioLight") which focuses on the completion of development and preparation of the Ocular D (the "Product") to the market, has announced that it has entered into an exclusive distribution agreement with Chemipal Ltd. for the exclusive distribution of the Product in Israel ("Distribution Agreement").

The Product is a nano-emulsion-based eye drops that is designed to treat dry eye in combination with vitamin D working to scatter and block blue light resulting from digital eye strain.

According to Lipicare's announcement, the distribution agreement is for an initial period of 9 years and includes, among other things, commitments by Chemipal to obtain approval from the Israeli Ministry of Health, marketing activities for the purpose of introducing the Product to the Israeli market and purchase minimum quantities annually at a contractual purchase price.

About Chemipal

As reported to the Company and to Lipicare, Chemipal was established in 1941 and is currently one of the largest distribution companies in Israel in the field of pharma, Chemipal's marketing division, which will market Lipicare's product, is one of Israel's leading entities in the field of import, marketing and sales of health products in the pharma industry. As reported by Chemipal, over the past 30 years, the division's marketing and sales team has launched and built many brands recognized by the Israeli consumer.



About Lipicare:

LipiCare Pharmaceuticals is engaged in the development of products based on nano-emulsions of Phospholipids aimed at enabling conveyance of fatty medications to the ocular surface in a manner that is both effective and comfortable for patients. LipiCare is focused on developing the first commercial product based on this technology, Ocular D, a product for treating dryness in the eye with integrated vitamin D. Lipicare is working to integrate additional products on the Lipicare platform and these are still in the initial research and development stages.

About BioLight

BioLight Life Sciences Ltd. is a leading company investing in companies and managing projects in the field of eye diseases and ocular treatments. BioLight's portfolio companies engage in advanced medical devices, medication, diagnostics and digital medicine designed to improve the efficacy and safety of treatments of eye diseases exemplifying the enormous potential of Israeli innovation in these fields.